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DIALYSIS – TRANSPLANTATION
Vitamin E–bonded hemodialyzer improves atherosclerosis
associated with a rheological improvement of circulating
red blood cells
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Vitamin E–bonded hemodialyzer improves atherosclerosis Atherosclerosis has much impact on mortality and
associated with a rheological improvement of circulating red morbidity of patients undergoing hemodialysis. Impor-
blood cells. tant determinants of the outcome in dialysis patients areBackground. Vitamin E–bonded hemodialyzer is known to
known to be cardiovascular disorders. Oxidative stress isimprove oxidative stress in patients with hemodialysis. How-
known to contribute to the development and progressionever, there is little information available as to whether or not
this membrane clinically improves atherosclerosis. Further- of atherosclerotic cardiovascular complications in hemo-
more, it remains unknown whether there is any effect of the dialyis patients [1]. Antioxidants such as vitamin E are
membrane on rheology of circulating red blood cells. reported to reduce the level of serum reactive-oxy-Method. We conducted a randomized, open-labeled, pro-
gen species (ROS) or oxidized low-density lipoproteinsspective control study (N  34) for 1 year to investigate the ef-
fect of vitamin E–bonded cellulose membrane dialyzer (EE) (Ox-LDLs) in patients with hemodialysis [2]. Although
(N 17) on carotid atherosclerotic changes [intima-media thick- it still remains unknown whether or not hemodialysis
ness (IMT) of carotid arteries] and the viscosity, percentage per se affects the progression of the complications, the
of dysmorphism (%DMR) of red blood cells (RBCs) and their
patients undergoing long-term hemodialysis tend to havedistribution width-standard deviation (RDW-SD), in compari-
more serious cardiovascular complicationss. This may beson with cellulose membrane (SU) (N  17) identical to EE
without vitamin E–bonded membrane. Erythropoietin (EPO) due to bioincompatibility between blood and dialysis
dose used for the treatment of uremic anemia was also calculated. membranes. The bioincompatibility contributes to the
Results. The IMT significantly decreased in the EE group, oxidative stress, which leads to atherosclerosis [3]. Me-while in the SU group the IMT significantly increased. The vis-
chanical contact of leukocytes with a dialysis membranecosity of RBCs in hemodialysis patients (4.70  0.45 cP) was
greater than that in healthy individuals (3.73  0.15 cP). EE induces the activation of ROS during hemodialysis [4].
significantly improved the viscosity (from 4.84  0.41 cP to In this regard, the development of a new biocompatible
4.51  0.54 cP, P  0.01), %DMR (from 2.29  2.17% to memebrane is necessary for reducing oxidative stress by
1.90  1.49%, P  0.01), and RDW-SD (from 54.4  7.6 fL
lowering the circulating ROS.to 49.3  5.9 fL, P  0.01). On the contrary, these parameters
Recently, vitamin E–bonded hemodialyzers have beenall worsened in the SU group. EPO dose needed for the treat-
ment of anemia was significantly (P  0.05) reduced from developed, which is known to have many favorable ef-
5383  2655 U/week to 4235  3103 U/week in the EE group. fects (i.e., the reduction of interleukin-6 release from
During these period, mean blood pressure, Kt/V urea, and serum monocytes [5] or improvement of endothelial dysfunc-2-microglobulin were not changed between the two groups.
tion [6] during hemodialysis). However, there is littleConclusion. These findings suggest that vitamin E–bonded
hemodialyzer is very useful for improving atherosclerosis from information available regarding to what extent they clini-
a clinical point of view. As one of the underlying mechanisms, cally improve atherosclerosis, although it has been re-
as well as antioxidant effects, we want to address an important cently reported that this membrane reduces a percentagerole of the improvement of rheology of circulating RBCs, which
increase in aortic calcification [7]. A significant increasemay also help to reduce the requirement of EPO dose in the
in the intima-media thickness (IMT) of the carotid ar-treatment of anemia of ESRD patients.
tery, a good indicator of atherosclerosis, is reported in
dialysis patients, as compared with age-matched healthyKey words: vitamin E, hemodialysis, atheroscrelosis, rheology, intima-
media thickness, viscosity, erythropoetin. subjects [8]. In the present study, we wanted to see how
IMT is affected by vitamin E–bonded hemodialyzers.Received for publication July 24, 2002
Furthermore, as one of the possibilities underlying mech-and in revised form October 6, 2002, and November 24, 2002
Accepted for publication December 13, 2002 anism(s) in which vitamin E–bonded dialyzer may exert
its favorable effects on atherosclerosis, we consider that 2003 by the International Society of Nephrology
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Table 1. Comparison of patient characteristics in vitamin E–bondedthis membrane affects the rheology of peripheral circula-
cellulose membrane dialyzer (EE) and a cellulose membrane
tion. Vitamin E–bonded membrane is known to change without vitamin E–bonded membrane (SU)
the oxidation of red blood cell (RBC) membranes [9].
Group EE SUThus, in terms of rheology, we have focused on viscosity,
Number 17 17dysmorphism (DMR) of RBCs, and the RBC distribu-
Age years 60.913.0 63.210.7 NS
tion width–standard deviation (RDW-SD) obtained from Gender male/female 10/7 9/8 NS
Duration of hemodialysis years 4.42.6 4.42.7 NSthe size distribution curve of RBCs since the viscosity
QB mL 18216 18624 NSof RBCs in the circulation may be related to injuries of Kt/V urea 1.310.13 1.280.13 NS
vascular endothelial cells, thus inducing the activation Serum 2-microglobulin 37.16.55 38.27.92 NS
PCR g/kg/day 1.080.03 1.090.02 NSof platelets, which then leads to thrombosis. In addition,
MBP mm Hg 1102 1123 NSthere is a possibility that an improvement of the rheology BMI 21.23.6 21.73.5 NS
may lead to affect erythropoietin (EPO) dose used dur- TC mg/dL 15037 15332 NS
TG mg/dL 12078 12371 NSing hemodialysis.
HDL mg/dL 4517 4414 NSThe aim of our present study is to investigate whether Alb g/dL 3.90.4 4.00.3 NS
vitamin E–bonded membrane retards the increase in
Abbreviations are: PCR, protein catabolic rate; MBP, mean blood pressure;
NS, not statistically significant; BMI, body mass index; TC, total cholesterol;IMT and to investigate the relationship between its vis-
TG, triglyceride; HDL, high-density lipoproteins; Alb, albumin.cosity, the percentage of DMR, and RDW-SD of RBCs
as well as EPO dose used for the treatment of uremic
anemia. To conduct these studies, we compared two
membranes, vitamin E–bonded and controlled mem- Hemodialysis-related factors
brane, which is identical except the surface modified with
In vitro data show that solutes clearance in both dia-
vitamin E, in a randomized, open-labeled, prospective lyzers (1.5 m2surface area) are 187 mL/min versus 185
study for 1 year. mL/min for urea, 172 mL/min versus 168 mL/min for
creatinine, and 91 mL/min versus 77 mL/min for vitamin
B12 in the CL-EE and CL-SU, respectively. All the pa-METHODS
tients used bicarbonate dialysate with a flow rate of 500Patients
mL/min. Blood flow rate during hemodialysis (QB) was
Thirty-four clinically stable patients in our hospital 3.5 mL/kg body weight. All these patients underwent
were randomly selected. The patients included 19 males 4-hour hemodialysis three times a week. Neither bacteria
and 15 females with a mean age of 62  12 years (range, nor pyrogen was detected in the dialysate prepared from
36 to 83 years). The mean time on hemodialyis treatment water obtained by reverse osmosis. No patient re-used
was 4.4  1.1 years, ranging from 0.9 to 8.9 years. The the dialyzer membrane, following the standard practice
causes of ESRD included chronic glomerulonephritis in Japan. Endotoxin concentration in the dialysate was
(N  26) and diabetes (N  8). No patient had hemato- below 5 EU/L by routine analysis with Limulus Amebo-
logic disorders such as lymphoma, myeloma, or other cyte Lysate assay (Wako Junyaku Endotoxin Measure-
related diseases. These patients were divided into two ment Kit, Tokyo, Japan). Efficacy of hemodialysis was
groups, according to dialysis membrane, a vitamin E– assessed by the calculation of Kt/V according to the
bonded membrane (CL-EE; Terumo Co., Ltd., Tokyo, equation of Daugirdas [10]. Under the same conditions
Japan) or control membrane, which was identical to the as described above, all patients were followed up for 12
CL-EE except that membrane was not bonded to vitamin months. Blood samples were drawn from the arterial site
E (CL-SU; Terumo Co., Ltd., Tokyo). There was no of arteriovenous fistula at the start and at the end of di-
statistical difference in the age and the mean hemodialy- alysis session at a 2-day interval. Serum was transferred
sis treatment time between each group (Table 1). Re- into plastic tubes and stored at 80C until its measure-
garding concurrent medications, eicosapentanoic acid ment. Only in the case of the measurement of RBC vis-
was given in six of 17 patients in the EE group and seven cosity described below, the assay was performed within
of 17 patients in the SU group, although statin was not 24 hours and no stored sample was used.
used. Prior to the study, there were three kinds of dia-
Evaluation of atherosclerotic changeslyzer used, regenerated cellulose membrane, polysul-
fone, and polymethylmetacrylate. However, there was Both carotid arteries were examined using a 7.5 MHz
statistically no difference between two groups. Both linear array transducer with high-resolution B-mode
groups were prospectively followed up for 1 year. All echography (Aloka, Tokyo, Japan). This device can mea-
the patients were informed of the purpose of the study sure the arterial wall thickness by 0.1 mm. The carotid
and gave their informed consent. The protocol for this arteries were examined bilaterally in the areas of the
common carotid artery (1 cm proximal to the dilatationstudy was approved by the Institutional Review Board.
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of the carotid bulb), the carotid bifurcation (1 cm proxi-
mal to the flow divider), and the internal carotid artery
(1 cm distal to the flow divider) according to the method
of Burke et al [11]. The IMT was defined as the distance
between the leading edge of the lumen-intima echo of
the near wall and the leading edge of the media-adventi-
tia echo. The measurements of IMT were made blindly
by two carefully trained sonographers. In a separate se-
ries of IMT measurements done in another patients,
the interobserver coefficient of variation was 8%. To
enhance the reproducibility of measurements, standard-
ized interrogation angles were used according to the
recommendations described previously [11]. The maxi-
mum thickness of the wall was recorded. The existence
of plaque was also recorded. In cases where it was hard to
tell the difference between plaques and thickened carotid
walls, except by being judged as apparent plaques, the
plaque was defined as the IMT of more than 1.5 mm.
The prevalence of plaques was recorded, but the size
was not.
The predialysis mean blood pressure was determined
as mean blood pressure diastolic (systolic-diastolic)/3.
Analysis of visicosity of RBCs
To measure the viscosity of RBCs, we used cone plate
type viscometer (Visconic ED, Tokyo Keiki, Tokyo, Ja-
pan). RBCs obtained after the removal of plasma and
buffy coat from heparinized blood were washed three
times with 0.9% NaCl solutions, and adjusted in 55%
Fig. 1. Representative erythrocytes shown by a scanning electron mi-hematocrit. According to the manufacturers’ instruction,
crosopy at a magnification of 5000. (a) Normal erythrocytes. (b) Dys-1.1 mL of RBC solution was added to viscometer at
morphic erythrocytes.
37C and viscosity was measured as a unit of cP (dyne •
sec/cm2) 2 minutes after the incubation. Preliminary stud-
EPO dose for the treatment of ESRD anemiaies showed that the incubation time required was
All the patients had been given EPO intravenously as2 minutes. Study of the reproducibility of measurements
hematocrit was maintained at 30% to 33% with a levelshowed variable values within 8% of cP. To find how
of ferritin between 100 ng/mL and 300 ng/mL. Everyoxidative stress would affect cP, we studied the change
2 weeks total counts of RBCs, hemoglobin, and hemato-of viscosity shown after an addition of 1 mmol/L CuSO4
crit were measured and ferritin level was checked everysolution.
3 months. If ferritin level was below than 100 ng/mL, we
Analysis of DMR of RBCs administered iron intravenously, measuring the ferritin
level every month. Under the conditions mentionedUsing a scanning electron microscopy, RBCs fixed
above, EPO requirements were adjusted every month.with 2% glutaraldehyde were observed at a magnifica-
tion of 2000. Representative DMR of RBCs obtained Statistical analysis
by hemodialysis patients is shown in Figure 1. A per-
All the data are expressed as mean SD. Differencescentage of any DMR of RBCs was measured according
between the two groups were analyzed by an unpairedto the method of Calzavara et al [12] and compared
and paired Student t test. Mann-Whitney U test was alsobetween the two groups.
used as necessary. The level of statistical significance was
defined as P  0.05. All the statistical analysis wereAnalysis of RBC size distribution curve
performed with SAS/Windows (version 6.12).
RDW-SD of histogram for RBCs distribution curve,
shown as a unit of fL, shows a degree of anisocytosis,
RESULTSwhich means a width of RBC distribution at a height of
20% from the bottom of the curve when the peak value All the 34 patients completed the study. Table 1 shows
the patient characteristics. There was no difference inof the distribution is 100%.
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Table 2. Effects of membrane on intima-media thickness (IMT) and erythropoietin (EPO)
EE SU
Before After Before After
EPO U/week 53832655 42353103 51622514 66182190
P  0.05 P  0.001
Ferittin ng/mL 13648 13040 12846 13241
NS NS
Right IMT mm 0.930.18 0.880.15 0.880.22 0.990.21
P  0.05 P  0.01
Prevalence of plaque % 35.3 41.2 29.4 35.3
NS NS
Left IMT mm 0.970.24 0.870.14 0.930.19 0.990.25
P  0.01 P  0.05
Prevalence of plaque % 29.4 35.3 35.3 35.3
NS NS
Abbreviations are: EE, vitamin E–bonded cellulose membrane dialyzer; SU, cellular membrane without vitamin E–bonded membrane; NS, not statistically
significant.
ages, duration of hemodialysis, and mean blood pressure.
Regarding hemodialysis efficacy, QB, Kt/V urea and se-
rum 2-microglobulin levels were not different between
the two groups. There was also no difference in body
mass index (BMI), total cholesterol, triglyceride, or albu-
min between the two groups.
As shown in Table 2, Vitamin E–bonded dialyzer sig-
nificantly (P  0.05) decreased IMT, while that of the
control group did not, but rather increased significantly.
The prevalence of carotid plaque did not change in both
the groups before and after this study.
Normal value of viscosity of RBCs was determined to
be 3.73  0.15 cP (N  7) using RBCs obtained from
healthy individuals. Regarding the validity of viscosity
measurement for oxidative stress, we confirmed that vis-
cosity increased from 3.73 to 7.45 cP 3 hours after
1 mmol/L CuSO4 addition as an oxidative stress to RBCs
obtained from healthy individuals. RBCs viscosity in all
these hemodialysis patients showed increased values,
which means that hemodialysis patients are clearly under
Fig. 2. The viscosity is decreasing in the vitamin E–bonded celluloseoxidative stress conditions. As shown in Figure 2, EE
membrane dialyzer (EE) group, while in the cellulose membrane with-
had been improving the viscosity from 4.84  0.41 cP to out vitamin E–bonded membrane (SU) group the viscosity is getting
worse.4.63  0.36 cP after 6 months, and to 4.51  0.54 cP
at 1 year after this study, reaching to the statistically
significant level (P 0.01). On the other hand, SU rather
aggravated the viscosity from 4.57  0.48 cP to 4.72 
improve the %DMR (1.98 1.44% before, 1.93 1.45%0.49 cP after 6 months, and to 4.90 0.53 cP after 1 year
after 6 months, and 1.88  1.46% after 1 year).(P  0.01)
Normal value of RDW-SD in health individuals wasThe percentage of DMR (%DMR) rate of RBCs
45.1  0.63 fL (N  7). As shown in Figure 4, RDW-SDshowed the same trends. Normal value of %DMR was
likewise improved significantly (P  0.01) in the EE0.77  0.43 (N  7) using RBCs obtained from healthy
group, from 54.4 7.6 fL to 49.1 7.0 fL after 6 months,individuals. As shown in Figure 3 a and b, RBCs from
and to 49.3 5.9 fL after 1 year. However, the SU grouphemodialysis patients in the SU group showed numerous
did not show any improvement (55.3  7.4 fL before,DMR, which were called largely echinocytes, compared
55.8  6.9 fL after 6 months, and 55.1  6.2 fL afterto those in the EE group (Fig. 3 c and d). EE significantly
1 year).decreased the %DMR from 2.29  2.17% to 2.16 
As shown in Table 2, EPO dose used for the correction1.79% after 6 months, and to 1.90  1.49% (P  0.01)
after 1 year, while the SU group did not statistically of anemia in ESRD was much reduced in the EE group,
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Fig. 3. Red blood cells (RBCs) in patients with hemodialysis show numerous dysmorphisms in the cellulose membrane without vitamin E–bonded
membrane (SU) group. (a) Magnification 2000. (b) Magnification 5000). In the vitamin E–bonded cellulose membrane dialyzer (EE) group,
RBCs dysmorphism is well preserved. (c) Magnification 2000. (d ) Magnification 5000).
from 5383  2655 U/week to 4235  3103 U/week (P  effect of the membrane on atherosclerosis, there is only
a report that vitamin E–bonded dialyzer significantly0.05). In the SU group, on the contrary, EPO dose sig-
reduces the percentage increase in aortic calcificationnificantly increased from 5162 2514 U/week to 6618
index (ACI) evaluated by computed tomography (CT) [7].2190 U/week (P  0.001). Serum levels of ferritin were
Regarding repeatability of IMT measurements, there maynot significantly different.
be a number of potential limitations to our study. How-
ever, we added important evidence by showing that IMT
DISCUSSION was improved in the EE group 1 year later in the prospec-
We demonstrated that vitamin E–bonded dialyzer was tive controlled study, although the prevalence of plaque
clinically useful for the retardation of atherosclerosis was not changed. Although blood pressure control is
shown in carotid IMT and to reduce EPO dose needed known to affect the progression of atherosclerosis, mean
for the correction of anemia in ESRD. We also showed blood pressure was not changed between the two groups
that these favorable effects may be ascribed to the im- nor was it altered between before or after this study.
provement of rheology of peripheral circulation. Thus, this favorable effect appears to be due to the use
There are insufficient data available as to whether of vitamin E–bonded dialyzer. Our results also confirmed
or not vitamin E–bonded dialyzer is indeed useful for the previous reports [13, 14] that EPO dose was reduced
atherosclerosis clinically found in ESRD patients, al- in patients using vitamin E–bonded dialyzer.
though there are many reports showing that this mem- The vitamin E–modified dialyzer consists of a block
brane clearly reduces an oxidative stress. Clinically, it polymer, which masks the hydroxyl groups on cellulose,
has been already reported that EPO dose used for the an oleyl alcohol that inhibits platelet aggregation, and a
vitamin E coating with antioxidant properties as re-correction of anemia decreased [13, 14]. Concerning the
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plasma levels of ox-LDL and malondialdehyde (MDA)
[7, 9, 20]. Therefore, we did not measure these plasma
levels of ox-LDL or MDA in the present study. Likewise
it is well known that this membrane improves neutrophil
function [20, 21] and reduces superoxide anion radicals
[20]. Despite numerous reports regarding the favorable
effects of vitamin E–bonded membrane on oxidative
stress assessed by such plasma levels as ox-LDL or ROS,
Dhondt et al [22] have recently reported that when com-
paring this membrane with polysulfone membrane re-
garding acute biocompatibility parameters, no superior-
ity of this membrane versus the biocompatible standard
polysulfone membrane could be shown.
Our interest regarding the underlying mechanisms in
which the membrane exerts its favorable effect has been
directed toward the rheology of circulating RBCs. There
are no data available for the effect of vitamin E–bonded
membrane on this field. Since RBCs show increased
membrane lipid peroxidation, reduced membrane fluid-
ity, and increased osmotic fragility [23–25] after hemodi-Fig. 4. In the vitamin E–bonded cellulose membrane dialyzer (EE)
alysis, we tried to look at the changes of RBCs viscositygroup, red blood cells and their distribution width-standard deviation
(RDW-SD) decreased significantly, while it was not changed in the after the long-term use of the membrane. As expected the
cellulose membrane without vitamin E–bonded membrane (SU) group. viscosity of RBCs was greater in hemodialysis patients,
as compared with that in healthy subjects. After this study,
cP increases in the SU group. Therefore, bioincompati-
bility during hemodialysis is also very important factorported by Sasaki, Hosoya, and Saruhashi [15]. The favor-
able effects of vitamin E–bonded hemodialyzer on ath- to influence rheologic changes, which may lead to the
progression of atherosclerosis. Unfortunately, we do noterosclerosis may be ascribed to the reduction of com-
plement and platelet activation. However, our results know the cP value at the induction of hemodialyis in
individual cases. It remains unknown to what extent cPdescribed here might be added to one of the underlying
mechanisms. The amount of vitamin E immobilized on had been changing until the beginning of this study after
hemodialysis induction. There might be a possibility thatthe surface-modified cellulose membrane was 147.5 
17.5 mg/m2. Although vitamin E supplementation de- cP had increased in patients using bioincompatible mem-
brane until the beginning of this study. At all events, wecreases the oxidative susceptibility of LDL in renal fail-
ure patients on dialysis therapy [2], it remains unknown clearly demonstrated that vitamin E–bonded dialyzer
had been decreasing the viscosity of RBCs as time goeshow much immobilized vitamin E corresponds to an
oral dose of vitamin E mentioned above. It is recently by as well as other parameters, including %DMR or
RDW-SD, while viscosity had been getting worse in thereported that vitamin E–bonded dialyzer provided more
effective antioxidant defense than peroral administra- control SU group. To see the importance of rheologic
changes of RBCs in reduction of IMT, we analyzed thetion of vitamin E in hemodialysis patients [9]. While
vitamin C, another antioxidant vitamin, is water-soluble, correlation between the two. However, there was no
correlation between any parameters of rheologic changesvitamin E is fat-soluble and bound to protein or lipopro-
tein. Therefore, no elimination is to be expected during and IMT. This may be due to the fact that the change
of IMT is too small. Our preliminary study shows thatdialysis. Decreased, normal, or even increased plasma
concentrations of vitamin E have been described in pa- patients with chronic renal failure prior to the induction
of hemodialysis have increased viscosity and DMR oftients on regular hemodialysis therapy [16–18]. It re-
mains unknown whether or not an increased plasma level RBCs. Therefore, these rheologic changes are not neces-
sarily ascribed to the mechanical influences caused byof vitamin E per se exerts its favorable effect on athero-
sclerosis in the EE group. However, we believe that local hemodialysis. Regarding the mechanisms of how the
changes of rheology could be related to atherosclerosis,contact of blood to this membrane play an important
role for the prevention of atherosclerosis. there is little direct data available. We speculate as fol-
lows. The increased viscosity of RBCs in the circulationThere is widespread acceptance of hypothesis that
ox-LDL within the arterial wall is a key early event leads to injuries of endothelium, which then activates
platelets or neutrophils. Indirectly, ROS or cytokinesin the development of atherosclerosis [19]. It has been
clearly known that vitamin E–bonded dialyzer decreased are released, or thrombus would be formed.
Kobayashi et al: Vitamin E–bonded hemodialyzer improves athersclerosis 1887
9. Mydlik M, Derzsiova K, Racz O, et al: A modified dialyzer withEPO dose used for the treatment was reduced in ac-
vitamin E and antioxidant defense parameters. Kidney Int 59
cord with an improvement of rheology mentioned above. (Suppl 78):S144–S147, 2001
10. Daugirdas J: Chronic hemodialysis prescription: A urea kineticIn other words EPO dose used in the EE group signifi-
approach, in Handbook of Dialysis, edited by Daugirdas J, Ingcantly decreased, while EPO dose used in the SU group
T, Boston, Little, Brown, 1994, p 94
significantly increased. Although it is reported that this 11. Burke GL, Evans GW, Riley WA, et al: Arterial wall thickness
is associated with prevalent cardiovascular disease in middle-agemembrane is associated with less clotting in hemodialysis
adults. The atherosclerosis risk in communities (ARIC) study.patients [14], the changed properties of RBCs membrane
Stroke 26:386–391, 1995
may contribute to the decreased viscosity or DMR, thus 12. Calzavara P, De Angeli S, Gatto C, et al: Morphologic evalua-
tion of red blood cells using vitamin E-modified dialysis filters, inincreasing erythrocyte survival [26]. Taken together,
Contributions in Nephrology, Vitamin E-bonded membrane, vol-there is a possibility that an improvement of rheology
ume 127, edited by Ronco C, La Greca G, Basel, Karger, 1999,
of circulating RBCs, as well as antioxidant effects, im- pp 172–176
13. Usberti M, Bufanco G, Lima G, et al: Increased red blood cellproved carotid IMT.
survival reduces the need of erythropoietin in hemodialyzed pa-
tients treated with exogenous glutathione and vitamin E-modified
membrane, in Contributions in Nephrology, Vitamin E-bondedCONCLUSION membrane, volume 127, edited by Ronco C, La Greca G, Basel,
Karger, 1999, pp 208–214We have shown that vitamin E–bonded hemodialyzer
14. Huraib S, Tanimu D, Shaheen F, et al: Effect of vitamin E-modified
used for 1 year improved the increased IMT of carotid dialyzers on dialyser clotting, erythropoietin and heparin dosage:
A comparative crossover study. Am J Nephrol 20:364–368, 2000arteries, and reduced the EPO dose required for the
15. Sasaki M, Hosoya N, Saruhashi M: Vitamin E modified cellulosetreatment of ESRD anemia. The improved viscosity and
membrane. Artif Organs 24:779–789, 2000
DMR of RBCs clearly shown in the present study may 16. Panzetta O, Cominacini L, Garbin U: Increased susceptibility of
LDL to in vitro oxidation in patients on maintenance hemodialysis:contribute to these favorable effects through the changed
Effects of fish oil and vitamin E administration. Clin Nephrolproperties of RBCs membrane by antioxidant effects so 44:303–309, 1995
far reported. 17. Stein G, Richter G, Funfstuck R, et al: Serum vitamin E levels
in patients with chronic renal failure. Int J Artif Organs 6:285–
Reprint requests to Shuzo Kobayashi, M.D., Ph.D., Vice Director, Sho- 287, 1983
nan Kamakura General Hospital, 1202-1 Kamakura, 247-8533 Japan. 18. Hultqvist M, Hegbrant J, Nilson Thorell C, Lindholm T:
E-mail: shuzo@shonankamakura.or.jp Plasma concentrations of vit C, E and MDA during hemodialysis.
Clin Nephrol 47:37–46, 1997
19. Regnstrom J, Nilsson J, Tornvall P, et al: Susceptibility to LDL
REFERENCES oxidation and coronary atherosclerosis in man. Lancet 339:1183–
1186, 19921. Becker B, Himmelefarb J, Henrich W, Hakim R: Reassessing the
20. Shimazu T, Ominato M, Toyama K, et al: Effects of a vitamincardiac risk profile in chronic hemodialysis patients: A hypothesis E-modified dialysis membrane on neutrophil superoxide anionon the role of oxidant stress and other non-traditional cardiac risk radical production. Kidney Int 59(Suppl 78):S137–S143, 2001factors. J Am Soc Nephrol 8:475–486, 1997 21. Tsuruoka S, Kawaguchi A, Nishiki K, et al: Vitamin E-bonded
2. Islam KN, O’Byrne D, Devaraj S, et al: Alpha-tocopherol supple- hemodialyzer improves neutrophil function and oxidative stress
mentation decreases the oxidative susceptibility of LDL in renal in patients with end-stage renal failure. Am J Kid Dis 39:127–
failure patients on dialysis therapy. Atherosclerosis 150:217–224, 2000 133, 2002
3. Hakim R: A clinical implication of hemodialysis membrane bio- 22. Dhondt A, Vanholder R, Glorieux G, et al: Vitamin E-bonded
compatibility. Kidney Int 44:484–494, 1993 cellulose membrane and hemodialysis bioincompatibility: Absence
4. Odetti P, Garibaldi S, Gurreri G, et al: Protein oxidation in of an acute benefit on expression of leukocyte surface molecules.
hemodialysis and kidney transplantation. Metabolism 45:1319– Am J Kid Dis 36:1140–1146, 2000
1322, 1996 23. Yawata Y, Howe R, Jacob H: Abnormal red cell metabolism
5. Girndt M, Lengler S, Kaul H, et al: Prospective crossover trial causing hemolysis in uremia. Ann Intern Med 79:362–367, 1973
of the influence of vitamin E-coated dialyzer membranes on T-cell 24. Giardini O, Taccone, Galluci M, Lubrano R: Evidence of red
activation and cytokine induction. Am J Kidney Dis 35:95–104, blood cell membrane lipid peroxidation in hemodialysis patients.
2000 Nephron 36:235–237, 1984
6. Miyazaki H, Matsuoka H, Itabe H, et al: Hemodialysis impairs 25. Peuchant E, Carbonneau MA, Dubourg L: Lipid peroxida-
endothelial function via oxidative stress: Effects of vitamin tion in plasma and red blood cells of patients undergoing hemo-
E-coated dialyzer. Circulation 101:1002–1006, 2000 dialysis: Vitamin A, E, and iron status. Free Radic Biol Med 16:339–
7. Mune M, Yukawa S, Kishino M, et al: Effect of vitamin E on 346, 1994
lipid metabolism and atherosclerosis in ESRD patients. Kidney Int 26. Taccone-Gallucci M, Meloni C, Lubrano R, et al: Chronic hemo-
56(Suppl 71):S126–S129, 1999 lysis and erythrocyte survival in hemodialysis patients treated with
8. Stenvinkel P, Heimbu¨rger O, Paultre F: Strong association be- vitamin E-modified dialysis filter, in Contributions in Nephrology,
tween malnutrition, inflammation, and atherosclerosis in chronic Vitamin E-bonded membrane, volume 127, edited by Ronco C, La
Greca G, Basel, Karger, 1999, pp 44–48renal failure. Kidney Int 55:1899–1911, 1999
